Economic Evaluation in U.S. Health Care: Principles and Applications
The steady flow of new pharmaceuticals and new technology has provided clinicians with an arsenal of effective treatments and diagnostic techniques. However, these interventions come at a price. With healthcare providers continuing to struggle with rising costs, clinical effectiveness alone will no longer be the only criteria for evaluating a drug or device. In the face of limited budgets, healthcare payers and providers will be expected to understand the value of new interventions in terms of economic, clinical, and quality of life benefits.Based on the core principles of pharmacoeconomics, this text provides an overview of the methodologies that can be applied to both drug and non-drug interventions. Economic Evaluation in U.S. Health Care: Principles and Applications offers health professionals a solid foundation for understanding, interpreting, and applying the tools of economic evaluation and is essential for anyone involved in healthcare decision-making.
What people are saying - Write a review
We haven't found any reviews in the usual places.
An Overview of the Economic Evaluation of Healthcare Interventions
Measuring Economic Outcomes
HealthRelated Quality of Life and Health Utility
Adjustments Within Economic Evaluation
The Industrys Involvement in Economic Evaluation
Other editions - View all
absenteeism Accessed January 17 Adverse Events alternatives assessment associated Available Bootman chronic clinical trials colonoscopy comorbidity cost-effectiveness analysis cost-minimization analysis cost-utility analysis costs and outcomes decision makers discount disease disease-specific economic evaluation economic information effectiveness employers estimated Food and Drug formulary decisions Health Aff Millwood health economic health outcomes health plans Health Policy health status health utility health-related quality healthcare costs healthcare interventions healthcare system HEOR hospital impact increased indirect costs instruments Ishikawa diagram lost productivity managed care Managed Care Pharmacy manufacturers MCOs measure Medicaid Medicare ment methods migraine National nomic organizations P&T committee patient-reported outcomes patients payers PBMs percent perspective pharmaceutical products Pharmacoeconomics pharmacy benefit PharmD physicians population prescription drug presenteeism propensity score public health QALYs questionnaire relevant risk factors specific standard gamble technologies therapy tion U.S. healthcare United vaccination